Tepotinib Plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
JOURNAL OF THORACIC ONCOLOGY(2023)
Key words
Tepotinib,MET amplification,NSCLC
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined